Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30079096HIVENSG00000180739.15protein_codingS1PR5NoNo53637Q9H228
TVIS20020750HPVENSG00000180739.15protein_codingS1PR5NoNo53637Q9H228
TCGA Plot Options
Drug Information
GeneS1PR5
DrugBank IDDB12371
Drug NameSiponimod
Target IDBE0002432
UniProt IDQ9H228
Regulation Typemodulator
PubMed IDs29138536; 29735753; 26856814
CitationsGajofatto A: Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date. Drug Des Devel Ther. 2017 Nov 2;11:3153-3157. doi: 10.2147/DDDT.S122249. eCollection 2017.@@Glaenzel U, Jin Y, Nufer R, Li W, Schroer K, Adam-Stitah S, Peter van Marle S, Legangneux E, Borell H, James AD, Meissner A, Camenisch G, Gardin A: Metabolism and Disposition of Siponimod, a Novel Selective S1P1/S1P5 Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism. Drug Metab Dispos. 2018 Jul;46(7):1001-1013. doi: 10.1124/dmd.117.079574. Epub 2018 May 7.@@O'Sullivan C, Schubart A, Mir AK, Dev KK: The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures. J Neuroinflammation. 2016 Feb 8;13:31. doi: 10.1186/s12974-016-0494-x.
GroupsApproved; Investigational
Direct ClassificationTrifluoromethylbenzenes
SMILESCCC1=CC(=CC=C1CN1CC(C1)C(O)=O)C(C)=NOCC1=CC=C(C2CCCCC2)C(=C1)C(F)(F)F
Pathways
PharmGKB
ChEMBLCHEMBL2336071